Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
n-of-1 trial to reduce nocebo-related statin intolerance
NL-OMON59545Phase 4Recruiting
- Sponsor
- Erasmus MC
- Start
- Dec 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of atorvastatin and rosuvastatin in familial hypercholesterolemia (FH) and cardiac morbidity (2 arms), sponsored by Erasmus MC. Primary endpoint: Self-reported statin use at 12 months. Started Dec 2024; status: recruiting.
02
Drugs
atorvastatinrosuvastatin
03
Conditions
familial hypercholesterolemia (FH)cardiac morbidity
Beyond the preview
Go deeper on NL-OMON59545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59545.